. : http://chem.msu.ru/rus/vmgu/125/344.pdf
: Wed Jun 20 11:58:27 2012
: Sun Apr 10 11:21:17 2016
: IBM-866




`

344

. . -. . 2. . 2012. . 53. 5


615.1


.. 1, .. 1, .. 2 .. 3 (1 . .. , ; 2 . .. ; 3 .. ; e-mail: eaureus@mail.ru)
- (, ), . , . in vivo , , , , .

: , , .

, (-, , ). (1-[(2,3,4-)] ( )), 20 20 . , [1]. , , , , , , [2]. , , [3].

, 35 - . 12 [4]. , [5]. : Beckman J-6B (), (Laboratory shaker type 358S, ), Series 200 Perkin Elmer (), , Pentium 4 MultiChrom, - Rheodyne (), 7125.


. . -. . 2. . 2012. . 53. 5

345

: , 35 ( ). , , 35 ( , , R). - R . 6 - 11,41,8 , 34 . , , 3,120,43 /. . () 12 . ( ). 12 . , . 2 . (T) (R). [6]. , 1,0 , ( ) 0,5; 1; 1,5; 2; 3; 4; 6; 10 24 . 5000 ./ 20. : (1,0 ) 0,1 0,25 N NaOH 3,0 . 15 10 5000 ./. (2,0 ) 55 [7]. 0,1 . 20 -

. : K = (tg /tg )100%, tg , tg . , ( ) 90,803,14%. . : Luna Phenomenex - C18(2) (4,6250 ; 5 ); 700 , KH2PO4 (0,02 M) 300 ; 6,0, ( ); 1,0 /; - 285 , ; 20 . (2223). . . ~6,40,4 . ~23 /. (in vitro) . 1. - ( M-IND) , [8, 9]: AUC(0-) (/) . AUC0 ; T () ; (/) ; T1/2 () , .. , ; K (-1) , .. -


346

. . -. . 2. . 2012. . 53. 5
1 ( p = 95%, n = 6, t = 2,57) (/) 100,0 (/) 98,5 97,9 504,7 498,2 1000,6 1002,0 100,7 99,4 493,5 503,9 1000,3 1006,7 104,2 102,7 496,7 499,9 999,7 990,1 101,05 SD 2,90 2,323 , % ( ) 2,299

500,0

499,48

4,29

3,434

0,687

1000,0

999,9

5,43

4,344

0,434

, ; /AUC(0) (-1) , . (T) (R) , :

AUC , /; D , /; C , /; C/AUC(0) , 1. Statistica v6.0. (M), (SD), (SEM), ( = 0,05), (%). t- , [9]. () (R) , , -

[10]. () (R) 3,12 / . 2. ( ) . . ( ) 3,12 /. ,

() (R) 3,12 / (n = 6, MSD): 1 - , , 2 -


. . -. . 2. . 2012. . 53. 5

347
2

() (R) 3,12 /


C



AUC

(0-)

T

1/2

k
0,0663 0,0743 0,0724 0,0631 0,0695 0,0667 0,0687 0,0042 0,0033

C

/AUC(0-)

() 1 2 3 4 5 6 SD = 0,05 3 3 3 3 3 3 3 0 - 872 946 864 1070 998 869 936,5 84,5 67,6 9836 9577 8015 9546 9133 8196 9050,5 768,0 614,5 (R) 1 2 3 4 5 6 SD = 0,05 3 3 3 3 3 3 3 0 - 901 898 726 931 881 854 865,2 72,7 58,2 9213 8271 8198 9620 8362 8193 8642,8 616,0 492,9 10,09 9,87 11,67 10,02 10,2 10,18 10,34 0,66 0,53 0,0687 0,0702 0,0594 0,0692 0,0679 0,0681 0,0672 0,0039 0,0032 0,0978 0,1086 0,0886 0,0968 0,1054 0,1042 0,1002 0,0073 0,0058 3 () (R) ? /R T R


10,45 9,33 9,57 10,99 9,97 10,39 10,12 0,61 0,49

0,0887 0,0988 0,1078 0,1121 0,1093 0,1060 0,1038 0,0087 0,0069





AUC

(0-)

T

1/2

/AUC(0 1,040 0,772 0,457

-))

1,000 - -

1,085 1,568 0,148

1,048 1,014 0,334

0,983 -0,601 0,562

() (R) . . . 3 : C,

, AUC(0), T1/2, k C/AUC(0-), , .


348

. . -. . 2. . 2012. . 53. 5
4 1 2 3 4 5 6 SD , = 0,05 F 106,76% 115,79% 97,77% 99,23% 109,22% 100,04% 104,80% 7,03% 5,63% F 96,78% 105,35% 119,01% 114,93% 113,28% 101,76% 108,52% 8,57% 6,86% F 90,65% 90,98% 121,73% 115,82% 103,72% 101,72% 104,10% 12,70% 10,16%

: (C), (), - (1/2), (AUC(0-)) C/AUC(0-) C. ~3 () 936,584,5 / 865,272,7 / . 1/2. 10,120,61 , 10,340,66 . AUC(0-). 9050,5768,0 /, 8642,8616,0 /. C/AUC(0-). 0,10380,0087 0,10020,0073 1 1. Fragasso G, Palloshi A, Puccetti P et al. // J. Am. Coll. Cardiol. 2006. 48. N 5. P. 992. 2. .., .., .., .. // . 2011. 4. . 52. 3. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. // Eur. J. Cardiovasc. Prev. Rehabil. 2008. 15. 5. . 533. 4. .., .., .. // . 2011. 9. . 35. 5. . . , . . , . . . : . ., 2011. 6.

. , , , . . 4 F, F F , . . 4, F (104,807,03%) 80-125%, F (108,528,57%) F (104,1012,70%) 75-133%. , , , , (, ) .

. ., 2001. 7. Jackson P.J., Brownsill R.D., Taylor A.R. et al. // Xenobiotica. 1996. 26. N 2. . 221. 8. ( ) / . . .. . ., 2005. 9. .., .., .., .., .. //. . -. 2. . 2011. 52. . 154. 10. .., .., .. . in vivo-in vitro // . 2010. 4. . 60.
15.05.12


. . -. . 2. . 2012. . 53. 5

349

CompaRative estimation of featuRes of phaRmaCokinetiCs of the modified mediCinal foRm tRimetazidine
e.v. Blynskaya, k.v. alekseev, t.p. kalmikova, s.e. kondakov (Department of the Russian Academy of Medical Sciences of Zakusov scientific research institute of pharmacology of the Russian Academy of Medical Science. Russia, Moscow; First Moscow State Medical University of Sechenov, Russia, Moscow;Department of Chemistry Lomonosov Moscow State University)
predutal (servier, france) and tablets of trimetazidine the modified liberation is spent comparative preparation studying. their estimation pharmacokinetics indicators, values of bioavailability is carried out. in experiences in vivo it is shown that processes of an absorption, distribution, a metabolism and deducing of trimetazidine at application of tablets of trimetazidine the modified liberation and predutal are identical also medicinal forms are bioequivalent.

key words: trimetazidine, pharmacokinetics, bioequivalence.
: - . . . . .. , . . (eaureus@mail.ru); - . . .. , . . (convieck@ yandex.ru); - . .. , . . (newlofty@mail.ru); - . . . , . . (ksekse@mail.ru).